Explore /
Poster
/ Results of a completed phase I study of LAM-002 (apilimod dimesylate), a first-in-class phosphatidylinositol-3-phosphate 5 kinase (PIKfyve) inhibitor, administered as monotherapy or with rituximab or atezolizumab to patients with previously treated follicular lymphoma or other B-cell cancers.

Results of a completed phase I study of LAM-002 (apilimod dimesylate), a first-in-class phosphatidylinositol-3-phosphate 5 kinase (PIKfyve) inhibitor, administered as monotherapy or with rituximab or atezolizumab to patients with previously treated follicular lymphoma or other B-cell cancers.

Authors

Catherine S. Magid Diefenbach

Perlmutter Cancer Center at NYU Langone Health, New York, NY

Catherine S. Magid Diefenbach , Jonathan B Cohen , Wael A. Harb , Stephen M. Ansell , Loretta J. Nastoupil , Jeremy S. Abramson , Nehal J. Lakhani , Marshall T. Schreeder , Taimur Sher , Dipti Patel-Donnelly , David Michael Aboulafia , Candace A. Fuchs , Darrell Nix , Sean Landrette , Patricia S Graham , Lydia B King , Peter L. Young , Langdon L. Miller , Henri Lichenstein , Sarah C. Rutherford

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT02594384

Citation

J Clin Oncol 38: 2020 (suppl; abstr 8017)

DOI

10.1200/JCO.2020.38.15_suppl.8017

Abstract #

8017

Poster Bd #

350

Abstract Disclosures

Similar Posters

Poster

2022 ASCO Annual Meeting

$Updated interim analysis of the randomized phase 1b/3 study of tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.$